152 related articles for article (PubMed ID: 37325333)
21. Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification.
Matzkin H; Chen J; Agai R; Ziv-Baran T; Mabjeesh NJ
PLoS One; 2019; 14(4):e0215582. PubMed ID: 31002732
[TBL] [Abstract][Full Text] [Related]
22. A Comparison Between Low-Dose-Rate Brachytherapy With or Without Androgen Deprivation, External Beam Radiation Therapy With or Without Androgen Deprivation, and Radical Prostatectomy With or Without Adjuvant or Salvage Radiation Therapy for High-Risk Prostate Cancer.
Ciezki JP; Weller M; Reddy CA; Kittel J; Singh H; Tendulkar R; Stephans KL; Ulchaker J; Angermeier K; Stephenson A; Campbell S; Haber GP; Klein EA
Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):962-975. PubMed ID: 28333019
[TBL] [Abstract][Full Text] [Related]
23. Short-course androgen deprivation therapy and the risk of death from high-risk prostate cancer in men undergoing external beam radiation therapy and brachytherapy.
Raldow AC; Zhang D; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
Brachytherapy; 2015; 14(6):781-7. PubMed ID: 26361718
[TBL] [Abstract][Full Text] [Related]
24. Localized and Locally Advanced Prostate Cancer: Treatment Options.
Achard V; Panje CM; Engeler D; Zilli T; Putora PM
Oncology; 2021; 99(7):413-421. PubMed ID: 33784675
[TBL] [Abstract][Full Text] [Related]
25. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes.
Olarte A; Cambeiro M; Moreno-Jiménez M; Arbea L; Pérez-Gracia JL; Gil-Bazo I; Pascual I; Aristu J; Martínez-Monge R
Brachytherapy; 2016; 15(2):127-35. PubMed ID: 26832677
[TBL] [Abstract][Full Text] [Related]
26. Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.
Keane FK; Chen MH; Zhang D; Moran BJ; Braccioforte MH; D'Amico AV
Cancer; 2015 Aug; 121(16):2713-9. PubMed ID: 25925789
[TBL] [Abstract][Full Text] [Related]
27. Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.
Halpern JA; Sedrakyan A; Hsu WC; Mao J; Daskivich TJ; Nguyen PL; Golden EB; Kang J; Hu JC
Cancer; 2016 Aug; 122(16):2496-504. PubMed ID: 27224858
[TBL] [Abstract][Full Text] [Related]
28. Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review.
Wilt TJ; Ullman KE; Linskens EJ; MacDonald R; Brasure M; Ester E; Nelson VA; Saha J; Sultan S; Dahm P
J Urol; 2021 Apr; 205(4):967-976. PubMed ID: 33350857
[TBL] [Abstract][Full Text] [Related]
29. Combination therapy-permanent interstitial brachytherapy and external beam radiotherapy for patients with localized prostate cancer.
Matzkin H; Keren-Paz G; Mabjeesh NJ; Chen J
Acta Chir Iugosl; 2005; 52(4):31-6. PubMed ID: 16673591
[TBL] [Abstract][Full Text] [Related]
30. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
Moris L; Cumberbatch MG; Van den Broeck T; Gandaglia G; Fossati N; Kelly B; Pal R; Briers E; Cornford P; De Santis M; Fanti S; Gillessen S; Grummet JP; Henry AM; Lam TBL; Lardas M; Liew M; Mason MD; Omar MI; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; van Der Kwast TH; van Der Poel HG; Willemse PM; Yuan CY; Konety B; Dorff T; Jain S; Mottet N; Wiegel T
Eur Urol; 2020 May; 77(5):614-627. PubMed ID: 32146018
[TBL] [Abstract][Full Text] [Related]
31. Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy.
Tward JD; O'Neil B; Boucher K; Kokeny K; Lowrance WT; Lloyd S; Cannon D; Stephenson RA; Agarwal N; Farr T; Petragallo R; Sherar NZ; Kunz I; Hofer A; Courdy S; Shrieve DC; Dechet C
Clin Genitourin Cancer; 2020 Aug; 18(4):274-283.e5. PubMed ID: 32335059
[TBL] [Abstract][Full Text] [Related]
32. Additional treatments and reimbursement rates associated with prostate cancer treatment for patients undergoing radical prostatectomy, interstitial brachytherapy, and external beam radiotherapy.
Goharderakhshan RZ; Grossfeld GD; Kassis A; Shinohara K; Roach M; Carroll PR
Urology; 2000 Oct; 56(4):622-6. PubMed ID: 11018618
[TBL] [Abstract][Full Text] [Related]
33. Health related quality of life in Japanese men with localized prostate cancer treated with current multiple modalities assessed by a newly developed Japanese version of the Expanded Prostate Cancer Index Composite.
Kakehi Y; Takegami M; Suzukamo Y; Namiki S; Arai Y; Kamoto T; Ogawa O; Fukuhara S
J Urol; 2007 May; 177(5):1856-61. PubMed ID: 17437836
[TBL] [Abstract][Full Text] [Related]
34. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
35. A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy.
Ciezki JP; Klein EA; Angermeier K; Ulchaker J; Chehade N; Altman A; Mahadevan A; Reddy CA
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1347-50. PubMed ID: 15590163
[TBL] [Abstract][Full Text] [Related]
36. Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer.
Gray PJ; Lin CC; Cooperberg MR; Jemal A; Efstathiou JA
Eur Urol; 2017 May; 71(5):729-737. PubMed ID: 27597241
[TBL] [Abstract][Full Text] [Related]
37. Economic evaluation of treatments for patients with localized prostate cancer in Europe: a systematic review.
Becerra V; Ávila M; Jimenez J; Cortes-Sanabria L; Pardo Y; Garin O; Pont A; Alonso J; Cots F; Ferrer M;
BMC Health Serv Res; 2016 Oct; 16(1):541. PubMed ID: 27716267
[TBL] [Abstract][Full Text] [Related]
38. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
39. Impact of national guidelines on brachytherapy monotherapy practice patterns for prostate cancer.
Tseng YD; Paciorek AT; Martin NE; D'Amico AV; Cooperberg MR; Nguyen PL
Cancer; 2014 Mar; 120(6):824-32. PubMed ID: 24301555
[TBL] [Abstract][Full Text] [Related]
40. Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis.
Cooperberg MR; Ramakrishna NR; Duff SB; Hughes KE; Sadownik S; Smith JA; Tewari AK
BJU Int; 2013 Mar; 111(3):437-50. PubMed ID: 23279038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]